LA JOLLA, Calif.—The 2025 Advanced Lateral Flow Conference (ALFC), the premier global event for rapid diagnostics, today announced that the ALFC 2025 exhibit floor is officially sold out. The bustling exhibit hall will feature a full slate of innovators across assay development, manufacturing, materials, instrumentation, and enabling technologies when ALFC 2025 convenes October 14–15 at the Hilton La Jolla Torrey Pines in La Jolla, California.
Strong interest from across the lateral flow ecosystem drove rapid booth reservations, reflecting the sector’s focus on manufacturability, real-world performance, and commercialization paths. To accommodate ongoing demand, ALFC has opened a waitlist for companies seeking booth space should additional capacity become available.
“This year’s sellout is a signal that rapid diagnostics is investing again,” said Mitzi Rettinger, Chief Revenue Officer at DCN Dx and chair of the ALFC Organizing Committee. “Teams are prioritizing technologies that shorten development cycles, improve lot-to-lot consistency, and scale.”
The exhibit hall anchors two days of programming that align with ALFC 2025’s theme, Catalyzing Growth: Tech Advancements, Funding, and Regulatory Roadmaps in LFA. In addition to technical sessions and an executive panel, the show floor will serve as a hub for product demos, sourcing conversations, and business development meetings.
“It’s a floor for sourcing, side-by-side comparisons, and vendor shortlisting,” Rettinger said. “You’ll meet the teams you actually build with: CDMOs, materials suppliers, and reader OEMs.”
ALFC 2025 will welcome attendees from more than 100 organizations, spanning industry, funders and venture capital, government agencies, non-profits, and academic institutions. On the show floor, exhibitors will showcase advances in conjugation chemistries, membranes and materials, readers and instruments, automation, and enabling tools designed for scalable manufacturing, and novel diagnostics.
Companies interested in joining the exhibitor waitlist or inquiring about other sponsorship opportunities, and members of the media seeking credentials can contact the ALFC team at contact@alfc2025.com or via the website. On-site media briefings and interview opportunities will be available.
For more information about ALFC 2025 and its sponsors, visit alfc2025.com.
About the Advanced Lateral Flow Conference
The Advanced Lateral Flow Conference (ALFC), presented by DCN Dx, is the leading global event for lateral flow diagnostic developers, manufacturers, and those driving their commercial success. This annual conference delivers cutting-edge insights through expert-led sessions and provides a platform for researchers and developers to exchange ideas and innovations. Attendees gain practical insights to advance their businesses, deepen their knowledge of rapid diagnostics, and connect with leading minds shaping the future of point-of-care testing.
The ALFC 2025 theme, Catalyzing Growth: Tech Advancements, Funding, and Regulatory Roadmaps in LFA, focuses on the three pillars driving real-world progress in diagnostics: capital, innovation, and regulatory clarity. From shifting FDA expectations to sustainable funding models and manufacturability challenges, the content will tackle the strategic decisions that shape successful lateral flow products.
Attendees include product managers, business development leads, investors, regulatory professionals, scientists, supply chain reps, and service providers from across the diagnostics ecosystem. These are the people responsible for turning ideas into impact, and ALFC is where they come to learn, connect, and get things done.
To learn more about ALFC, visit alfc2025.com.
About DCN Dx
DCN Dx, based in Carlsbad, California, specializes in lateral flow diagnostics development and manufacturing, and IVD regulatory consulting and clinical research. DCN Dx’s multidisciplinary CDMO specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays. Their clinical research services group specializes in the planning, execution, and oversight of IVD clinical trials, inclusive of clinical operations, data management, and biostatistics, and regulatory services.
DCN Dx’s personalized approach to IVD product development and clinical trials has supported hundreds of programs and clients. They can oversee every stage from concept to assay development and platform integration, through clinical trials to manufacturing or only handle the aspects you request. In addition to lateral flow assays, DCN Dx’s clinical research expertise extends to any in vitro diagnostic, all with a focus on innovation, usability, and performance.
With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com.
